Edgewise Therapeutics (EWTX)

• Market cap: $3.05B
• 1 day: 0.35%
• 5 days: -2.61%
• 1 month: 16.9%
• 3 months: 76.24%
• 6 months: 106.31%
• Year to date: 21.18%
• 1 year: 1.27%
• 5 years: -4.07%
• 10 years: -4.07%
• Sector: Healthcare
• Industry: Biotechnology

About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Employees: 136